SCHEMBL4907027

SCHEMBL4907027

COc1ccccc1-c1nc(NC2CC2)nc(Cl)c1C#N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 1/20 0.47
▸ ADORA1 P30542 1/20 0.47
▸ HTT P42858 1/20 0.45
▸ AGER Q15109 1/20 0.44
▸ HPGD P15428 6/20 0.44
▸ ALDH1A1 P00352 6/20 0.44
▸ KDM4E B2RXH2 4/20 0.44
▸ TSHR P16473 4/20 0.44
▸ HSD17B10 Q99714 3/20 0.44
▸ CYP1A2 P05177 3/20 0.43
▸ USP2 O75604 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ CLK4 Q9HAZ1 2/20 0.43
▸ LMNA P02545 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4907005 0.84 ACHE (0.41) ADORA2AADORA1HPGDALDH1A1KDM4E
SCHEMBL4904086 0.84 ACHE (0.43) HTTHPGDALDH1A1CYP1A2MAPT
SCHEMBL4909514 0.82 ADORA1 (0.50) ADORA2AADORA1HPGDALDH1A1KDM4E
SCHEMBL4898198 0.79 HPGD (0.41) ADORA2AADORA1HPGDALDH1A1KDM4E
SCHEMBL4912631 0.78 ADORA2A (0.57) ADORA2AADORA1HTTHPGDALDH1A1
SCHEMBL4908900 0.76 HTT (0.60) ADORA2AADORA1HTTHPGDALDH1A1
SCHEMBL4906222 0.76 ALDH1A1 (0.45) ADORA2AADORA1AGERHPGDALDH1A1
SCHEMBL4906201 0.75 KMT2A (0.55) ADORA2AADORA1HPGDALDH1A1CYP1A2
SCHEMBL4906255 0.74 ADORA1 (0.47) ADORA2AADORA1HPGDALDH1A1CLK4
SCHEMBL4899212 0.74 KDM1A (0.47) ADORA2AADORA1HPGDALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 — — EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 — — US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ADORA2A 837/4885ADORA1 529/4885HTT 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback